ResultsIQ

ResultsIQ › Latest results › Borosil Scientific Limited

Borosil Scientific Limited Q3 FY26 results deck summary

NSE: BOROSCI · BSE: 544184

Results deck of 13 Feb 2026, summarised by AI from the filing.

Borosil Scientific's 9MFY26 Standalone EBITDA grew despite one-time Ambad expenses, while Consolidated EBITDA declined on lower Goel Scientific sales; medium-term revenue CAGR target is 12-14%.

Key takeaways

  1. Guidance Management targets a medium-term revenue CAGR of 12-14% and improvement in EBITDA margins
  2. Process Systems Process Systems revenue declined with a sales reversal of INR 3.75 cr in Q3FY26 under Ind AS and deferral of certain high value orders to subsequent quarters
  3. Growth drivers Growth is expected from Make in India, the Borosil brand, new product development and exports, with Biopharma SHAKTI in the Union Budget 2026-27 supporting biologics and biosimilars products

Original filing on BSE

Borosil Scientific Limited Q1 FY27 results

As filed: Revenue ₹107 cr (+11% year on year), EBITDA ₹8.5 cr (+69% year on year), PAT ₹4.4 cr, EBITDA margin 7.9% (+271 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹143 cr (+11% year on year), EBITDA ₹32.1 cr (+101% year on year), PAT ₹27.3 cr (+203% year on year), EBITDA margin 22.4% (+1,000 bps). Score 79 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Tax rate 7%. Not enough history for a trend yet: scored on growth alone. Share price after the results: +29.6% in 30 days (Nifty 500: +2.8%).
  • Q3 FY26: Revenue ₹121 cr (+20% year on year), EBITDA ₹17.2 cr (+72% year on year), PAT ₹8.7 cr (+108% year on year), EBITDA margin 14.2% (+428 bps). Score 89 of 100, Above trend. EBITDA margin rose 428 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −1.2% in 30 days (Nifty 500: −10.1%).
  • Q2 FY26: Revenue ₹107 cr (+4% year on year), EBITDA ₹8.0 cr (−47% year on year), PAT ₹3.0 cr (−67% year on year), EBITDA margin 7.5% (−709 bps). Score 0 of 100, Below trend. EBITDA margin fell 709 bps year on year. Other income 40% of PBT. Tax rate 40%. Consolidated profit -67% but standalone +0%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −7.8% in 29 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹96.0 cr (−8% year on year), EBITDA ₹5.0 cr (−50% year on year), PAT −₹4.0 cr (−57% year on year), EBITDA margin 5.2% (−441 bps). Score 6 of 100, Below trend. EBITDA margin fell 441 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 26% from last quarter. Share price after the results: −7.5% in 30 days (Nifty 500: +2.8%).
  • Q4 FY25: Revenue ₹118 cr, EBITDA ₹21.0 cr, PAT ₹14.0 cr, EBITDA margin 17.8%. Not scored. No result for the same quarter last year. Share price after the results: −4.5% in 30 days (Nifty 500: +1.4%).
  • Q3 FY25: Revenue ₹94.0 cr, EBITDA ₹11.0 cr, PAT ₹7.0 cr, EBITDA margin 11.7%. Not scored. No result for the same quarter last year.
  • Q2 FY25: Revenue ₹87.0 cr, EBITDA ₹13.0 cr, PAT ₹8.0 cr, EBITDA margin 14.9%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Borosil Scientific Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.